Shares of Maplight Therapeutics, Inc. (NASDAQ:MPLT – Get Free Report) have been assigned an average rating of “Buy” from the fifteen ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, nine have given a buy recommendation and four have assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $38.80.
Several research firms recently weighed in on MPLT. Needham & Company LLC upped their price target on Maplight Therapeutics from $37.00 to $42.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Canaccord Genuity Group assumed coverage on Maplight Therapeutics in a research note on Thursday, March 19th. They set a “buy” rating and a $35.00 price objective for the company. Raymond James Financial started coverage on Maplight Therapeutics in a report on Wednesday, June 24th. They issued a “strong-buy” rating and a $46.00 target price on the stock. Lifesci Capital upgraded Maplight Therapeutics to a “strong-buy” rating in a report on Thursday, May 14th. Finally, TD Cowen initiated coverage on Maplight Therapeutics in a research report on Tuesday, April 7th. They issued a “buy” rating for the company.
Read Our Latest Stock Report on Maplight Therapeutics
Maplight Therapeutics Price Performance
Maplight Therapeutics (NASDAQ:MPLT – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.43). Research analysts expect that Maplight Therapeutics will post -5.13 earnings per share for the current fiscal year.
Insider Activity
In other news, insider Erin Pennock Foff sold 4,438 shares of the company’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $28.54, for a total value of $126,660.52. Following the transaction, the insider owned 346,059 shares in the company, valued at approximately $9,876,523.86. This represents a 1.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider James Woodruff Lillie sold 24,811 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total transaction of $713,564.36. Following the sale, the insider directly owned 243,450 shares of the company’s stock, valued at $7,001,622. This trade represents a 9.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 495,244 shares of company stock valued at $14,079,461 in the last quarter. 3.80% of the stock is owned by company insiders.
Institutional Trading of Maplight Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the business. Strs Ohio purchased a new position in Maplight Therapeutics in the 4th quarter worth about $53,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Maplight Therapeutics in the 4th quarter worth $70,000. New York State Common Retirement Fund purchased a new position in shares of Maplight Therapeutics in the fourth quarter worth $93,000. MetLife Investment Management LLC purchased a new position in shares of Maplight Therapeutics in the fourth quarter worth $172,000. Finally, Walleye Capital LLC bought a new position in shares of Maplight Therapeutics during the fourth quarter worth $205,000.
About Maplight Therapeutics
We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.
Featured Articles
- Five stocks we like better than Maplight Therapeutics
- PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth
- Dollar Tree’s Turnaround Is Starting to Take Root
- Why Levi’s Digital Strategy Is Paying Off in a Big Way
- Constellation Brands: Beer Growth and Buybacks Mask Stock’s Slump
Receive News & Ratings for Maplight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maplight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
